Merck’s (MRK) Gardasil franchise includes vaccines for the prevention of certain strains of HPV (human papillomavirus) infections that are sexually transmitted. These HPV strains are responsible for cervical cancers and other HPV-induced infections such as anal, penile, vulvar, and vaginal cancers and genital warts.
The Gardasil franchise reported total sales of $469 million during 2Q17, representing 20% growth in revenues at constant exchange rates, compared with $393 million in 2Q16. These revenues reported growth due to increased sales of Gardasil-9 in US markets. Other vaccines for the prevention of HPV infection include Cervarix from GlaxoSmithKline (GSK).
Other human vaccines
Merck’s total human vaccines reported revenues of ~$1.32 billion for 2Q17, compared with $1.17 billion in 2Q16. Revenue growth was driven by strong sales in the Gardasil franchise as well as of Pneumovax 23, ProQuad-Varivax, and Zostavax. These revenues were partially offset by lower sales of RotaTeq in 2Q17.
Pneumovax 23 is a pneumococcal vaccine that protects from infections caused by germs and bacteria referred to as pneumococcus. Other pneumococcal vaccines include Prevnar 13, a blockbuster from Pfizer’s (PFE) portfolio, and Synflorix from GlaxoSmithKline (GSK).
Zostavax is a live attenuated virus vaccine used to prevent herpes zoster infections in adults over 50 years age.
To divest company-specific risks, investors can consider ETFs like the VanEck Vectors Pharmaceuticals ETF (PPH), which has 5.2% of its total assets in Merck (MRK). PPH also has 5.7% in AbbVie (ABBV), 5.7% in Novo Nordisk (NVO), 5.5% in Pfizer (PFE), and 4.7% in GlaxoSmithKline (GSK).